Detalhe da pesquisa
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
3.
Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort.
Rheumatology (Oxford)
; 63(1): 85-92, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094184
4.
The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study.
Rheumatology (Oxford)
; 63(4): 991-998, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341637
5.
Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.
Rheumatology (Oxford)
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754125
6.
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218744
7.
Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.
Rheumatology (Oxford)
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490262
8.
How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
Rheumatology (Oxford)
; 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38191998
9.
Patient-Initiated Follow-Up.
J Rheumatol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621794
10.
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
Clin Exp Rheumatol
; 42(3): 696-701, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019168
11.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696588
12.
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership.
Rheumatology (Oxford)
; 62(8): 2716-2723, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453848
13.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35766811
14.
An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis.
Rheumatology (Oxford)
; 2023 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38011669
15.
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations.
J Rheumatol
; 50(3): 438-450, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455946
16.
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey.
Dermatology
; 239(4): 621-634, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075723
17.
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Ann Rheum Dis
; 81(3): 359-369, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819273
18.
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Br J Dermatol
; 187(3): 438-441, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257363
19.
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Ann Rheum Dis
; 80(5): 582-590, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33334727
20.
JAK1 selective inhibitors for the treatment of spondyloarthropathies.
Rheumatology (Oxford)
; 60(Suppl 2): ii39-ii44, 2021 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33950224